100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Summary NURS 615 Test 1 Study Guide $13.99   Add to cart

Summary

Summary NURS 615 Test 1 Study Guide

 0 view  0 purchase

This is a comprehensive and detailed study guide on Test 1 for Nurs 615. ***An Essential Study Resource!!

Preview 3 out of 26  pages

  • November 14, 2024
  • 26
  • 2023/2024
  • Summary
All documents for this subject (12)
avatar-seller
anyiamgeorge19
CHAPTER 2
FDA
 Protecting and promoting public health through regulation of
o Food Safety, Tobacco products, RX and OTC drugs/medications, Vaccines,
Biopharmaceuticals, Blood Transfusions, Cosmetics, Electromagnetic imaging devices,
Animal food/feeds, Veterinary Products
o Collect medications and monitor the safety of drugs using Post-marketing surveillance by
med watch programs
o Determines the official labeling for all RX and OTC medication
o No regulation over herbal supplements
Off-Label
 Off Label use is the prescription of drugs for unapproved indications, age groups, dose, route
of administration
 Both Prescription and OTC drugs can be used in off-label ways
 Off-label is legal unless it violates ethical or safety guidelines
 There can be health risks or differences in legal liability
 (Cytotec being used for labor, but off label used for peptic ulcer disease)
Schedules




WHO
 Who prescribing process
o 1. Define the problem/diagnosis (Define the patient’s problem) (physical exam)
o 2. Specify therapeutic objective
o 3. Choose the treatment (Choose which drug or treatment is needed)
o 4. Start the treatment
o 5. Educate the patient
o 6. Monitor the effectiveness (monitor treatment)

,Drug development
 Phase 1- The drug is tested on healthy volunteers
o Evaluate safety, tolerance, pharmacodynamic effects (effects of drug on the body,
heart, blood pressure, ECG), absorption, distribution, metabolism, and excretion
o Must complete Investigation New Drug Application
 Summarizes the established preclinical and manufacturing information along
with the investigator's guidance
o Trials will be stopped if the half-life is too short or too long or poor bioavailability
o Stopped with significant ECG changes and severe adverse effects
o Start with sub-pharmacological doses that are escalated following multiple doses
o Cost- 500,000-1.5M
 Phase 2- Trials with people who have the disease for which the drug is thought to be
effective
o Efficacy and Safety on the target population
o Single maximal tolerated dose/several dose levels are tested on the target
population
o Progress to stage 3 depends on- drug efficacy relative to competitors, safety profile,
probability of technical and regulatory success, remaining patent life of the drug,
cost of goods to produce the drug, market share, price, reimbursement
 Phase 3- Large number of patients in medical research centers receive the drug in phase 3.
This larger sampling provides information about infrequent or rare adverse effects. The FDA
will approve a new drug application if phase 3 studies are satisfactory.
o Minimum of two trials
o Several Thousand Patients
o Confirms clinical doses, frequency, and timing of administration for approval
o Designed to test the hypothesis of efficacy
o Adverse effects are collected to assess benefit-risk potential
 Phase 4- This phase is voluntary and involves postmarket surveillance of the drug’s
therapeutic effects at the completion of phase 3. The pharmaceutical company receives
reports from doctors and other healthcare professionals about the therapeutic results and
adverse effects of the drug. Some medications, for example, have been found toxic and have
been removed from market after their initial release.
Infants/Children
 Issues in pediatric prescribing
o Drug formulated and packaged primarily for adults (not tested on pediatric
population)
o Less physiologically tolerate medication error due to developing renal, immune, and
hepatic functions

, o There is a lack of safety and efficacy studies in the patient population most
medications are studied in adult populations – age-related differences and
medication metabolism and mechanisms of action don’t necessarily apply to
pediatric populations
o Kids do not have fully mature liver and renal function and are at high risk for toxicity
and adverse drug effects
 Doses based on weight (mg/kg)
 Physiological differences
o Infants have more water, less fat
o Immature liver makes fewer serum proteins, is less able to metabolize drugs
o Blood-Brain barrier less well-developed in infants
o Renal function not fully developed until 30 months
 Pediatric Absorption
o Gastric pH does not reach adult level until age 1 year
 Acidic environment is needed to absorb the medication less medication will
be absorbed by the infant
o Children have a greater body surface area and will have greater absorption of topical
medication
 Infant skin more permeable leading to greater absorption of topical
medications (increased hydration and thinner stratum corneum)
 Immature peripheral circulation will prevent the absorption of IM or SQ
medications
 Pediatric Distribution
o Differences in Body Water and Fat
o Immature Liver function
 Age 0-6 months less albumin and fewer plasms proteins
 Fever binding sites in pediatric patients result in higher blood concentrations
of two or more drugs or less affinity for one of the drugs
o Immature Blood-Brain Barrier
o Birth: the blood-brain barrier is not developed leading to greater risk of CNS toxicity;
drug enters the CNS (Increased risk of drugs entering CNS)
 Phase 1 Metabolism
o Cytochrome P-450 (CYP) 3A enzymes play a major role in drug metabolism
 The 3A system, 3A4 is low in neonates and does not reach adult levels until
about 6-12months
o CYP3A7 earliest isozyme to show activity and present in utero (declines rapidly after
birth)
o CYP3A7 decreases throughout the first 6 months with an increase in CYP3A4 and
CYP3A5

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller anyiamgeorge19. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $13.99. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

72042 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$13.99
  • (0)
  Add to cart